News
The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...
For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...
Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
18h
HealthDay on MSNGLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...
14h
MedPage Today on MSNGLP-1 Maker Accused of Bribing Docs; FDA Warns on Unapproved Meds; PFAS in Devices
The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...
(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...
Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...
The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results